X4 Pharmaceuticals Inc. (XFOR)
X4 Pharmaceuticals Statistics
Share Statistics
X4 Pharmaceuticals has 173.66M shares outstanding. The number of shares has increased by 1.55% in one year.
| Shares Outstanding | 173.66M |
| Shares Change (YoY) | 1.55% |
| Shares Change (QoQ) | 1.21% |
| Owned by Institutions (%) | 49.68% |
| Shares Floating | 115.02M |
| Failed to Deliver (FTD) Shares | 397 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 11.42M, so 6.7% of the outstanding shares have been sold short.
| Short Interest | 11.42M |
| Short % of Shares Out | 6.7% |
| Short % of Float | 9.69% |
| Short Ratio (days to cover) | 8.64 |
Valuation Ratios
The PE ratio is -3.94 and the forward PE ratio is -0.83. X4 Pharmaceuticals's PEG ratio is 0.06.
| PE Ratio | -3.94 |
| Forward PE | -0.83 |
| PS Ratio | 57.68 |
| Forward PS | 0.2 |
| PB Ratio | 6.66 |
| P/FCF Ratio | -1.12 |
| PEG Ratio | 0.06 |
Enterprise Valuation
X4 Pharmaceuticals Inc. has an Enterprise Value (EV) of 107.91M.
| EV / Earnings | -2.88 |
| EV / Sales | 42.2 |
| EV / EBITDA | -2.96 |
| EV / EBIT | -2.96 |
| EV / FCF | -0.82 |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.41 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 10.73 |
| Cash Flow / Debt | -49.19 |
| Interest Coverage | 4.15 |
Financial Efficiency
Return on equity (ROE) is -1.69% and return on capital (ROIC) is -147.94%.
| Return on Equity (ROE) | -1.69% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | -147.94% |
| Revenue Per Employee | $17,881.12 |
| Profits Per Employee | $-261,888.11 |
| Employee Count | 143 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | 310K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -81.29% in the last 52 weeks. The beta is 0.39, so X4 Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | -81.29% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.59 |
| Relative Strength Index (RSI) | 31.03 |
| Average Volume (20 Days) | 3.59M |
Income Statement
In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M and earned -37.45M in profits. Earnings per share was -0.19.
| Revenue | 2.56M |
| Gross Profit | 1.76M |
| Operating Income | -36.4M |
| Net Income | -37.45M |
| EBITDA | -36.4M |
| EBIT | -36.4M |
| Earnings Per Share (EPS) | -0.19 |
Balance Sheet
The company has 55.7M in cash and 2.66M in debt, giving a net cash position of 53.04M.
| Cash & Cash Equivalents | 55.7M |
| Total Debt | 2.66M |
| Net Cash | 53.04M |
| Retained Earnings | -515.36M |
| Total Assets | 178.16M |
| Working Capital | 113.71M |
Cash Flow
In the last 12 months, operating cash flow was -130.9M and capital expenditures -326K, giving a free cash flow of -131.23M.
| Operating Cash Flow | -130.9M |
| Capital Expenditures | -326K |
| Free Cash Flow | -131.23M |
| FCF Per Share | -0.65 |
Margins
Gross margin is 68.83%, with operating and profit margins of -1.42K% and -1.46K%.
| Gross Margin | 68.83% |
| Operating Margin | -1.42K% |
| Pretax Margin | -1.45K% |
| Profit Margin | -1.46K% |
| EBITDA Margin | -1.42K% |
| EBIT Margin | -1.42K% |
| FCF Margin | -5.13K% |
Dividends & Yields
XFOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -73.08% |
| FCF Yield | -294.48% |
Analyst Forecast
The average price target for XFOR is $3, which is 1053.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 1053.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 14, 2019. It was a backward split with a ratio of 1:6.
| Last Split Date | Mar 14, 2019 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -5.21 |
| Piotroski F-Score | 2 |